The Cigna Group CI
Healthcare · Healthcare Plans · United States · S&P 500
Based on the available data, The Cigna Group gets an algorithmic score of 55/100. It trades at 275.26 $, with a bearish technical trend (RSI 48.4) and 32.8% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Sustained revenue growth (15.1% compound annual).
- Attractive free-cash-flow yield (11.5%).
- Low valuation (P/E 8.2).
- Low beta (0.17): defensive profile.
Weaknesses
- Thin net margin (2.3%): vulnerable to costs.
Fundamentals
| P/E | 11.39 |
| Forward P/E | 8.24 |
| PEG | 0.75 |
| P/B | 1.70 |
| EV/EBITDA | 7.65 |
| P/S | 0.26 |
| ROE % | 16.76 |
| ROA % | 4.46 |
| Gross margin % | 9.14 |
| Operating margin % | 3.98 |
| Net margin % | 2.27 |
| Revenue growth % (y/y) | 6.70 |
| Earnings growth % (y/y) | 10.20 |
| Revenue CAGR % | 15.15 |
| Earnings CAGR % | -3.86 |
| Debt/Equity % | 74.29 |
| Current ratio | 0.85 |
| FCF yield % | 11.53 |
| Dividend yield % | 2.27 |
| Payout % | 25.39 |
Returns
| 1 month | -0.8 % |
| 3 months | +0.4 % |
| 6 months | +7.9 % |
| YTD | +0.3 % |
| 1 year | -1.6 % |
| 3 years | +0.8 % |
| 5 years | +49.3 % |
Risk
| 1-year volatility | 32.8 % |
| Beta | 0.17 |
| 5-year max drawdown | -32.1 % |
| Sharpe 1A | -0.00 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.